Velocity Financial VEL 深 沪
等待开盘 10-18 09:30:00 美东时间
17.96
-0.140
-0.77%
华盛通- 最 高18.22
- 今 开18.10
- 成交量 7.17万股
- 最 低 17.96
- 昨 收 18.10
- 总市值 6.90亿
- 52周最高 20.98
- 市盈率 静 9.50
- 换手率 0.19%
- 52周最低 16.12
- 委 比 25.00%
- 总股本 3843.86万
- 历史最高 20.98
- 量 比 0.92
- 振 幅 1.44%
- 历史最低 2.24
- 每 手 1
- 风险率 2.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Health Canada Extends Review of CLINUVEL’s SCENESSE® for EPP
Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an update. CLINUVEL Pharma...
10-16 10:47
S&P Global Buys With Intelligence In $1.8 Billion Deal
SPGI to acquire With Intelligence for $1.8 billion, expanding into private markets and enhancing data solutions.
10-16 02:55
igma Lithium Recognized For Sustainability Excellence In Brazil Report, Upgrades Mining Operations To Boost Efficiency, Safety Ahead Of 2026 Expansion, Strengthens Global Energy Transition Role
Sigma Lithium Corporation (NASDAQ:SGML, BVMF: S2GM34)), a leading global lithium producer dedicated to powering the next generation of electric vehicles with carbon neutral, socially and environmentally sustainable
10-06 16:05
CLINUVEL Pharmaceuticals Announces Management Update and Strategic Focus
Clinuvel Pharmaceuticals ( ($AU:CUV) ) just unveiled an announcement. CLINUVEL ...
10-01 07:47
MoonLake rebounds despite downgrades prompted by trial setback
MoonLake Immunotherapeutics (NASDAQ:MLTX) traded higher on Tuesday even as Wall Street opted to downgrade the Swiss biotech following a late-stage trial setback for its lead candidate, sonelokimab, wh...
10-01 01:34
利空突袭！深夜，暴跌89%！
突然“爆雷”！ 周一美股，市值近40亿美元（约合人民币285亿元）的生物技术公司MoonLake暴跌89%。此前，该公司发布的一款实验性皮肤病药物的Ⅲ期...
09-29 22:47
MoonLake plunges after mixed results from skin disease trial
MoonLake Immunotherapeutics (NASDAQ:MLTX) saw its stock price drop on Monday following the results from late-stage studies testing sonelokimab, a treatment for adults suffering from moderate to severe...
09-29 21:03
Reported Sunday, MoonLake Phase 3 VELA Trials Show Sonelokimab Achieves Statistically Significant HiSCR75 Responses In Moderate To Severe Hidradenitis Suppurativa
VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first Phase 3 program using the higher
09-29 14:35
CLINUVEL Advances Novel Sustained-Release Drug Formulations
An announcement from Clinuvel Pharmaceuticals ( ($AU:CUV) ) is now available. C...
09-29 07:58
超4000款新品首发！2026春夏上海时装周开启今秋时尚盛会
转自：新华财经 新华财经上海9月23日电（李一帆）作为“上海之夏”国际消费季十大标杆活动之一，2026春夏上海时装周将于10月9日正式揭幕。本季时装周以“拓界...
09-23 09:23
